Inhibition of Hypoxia-inducible Factors Limits Tumor Progression in a Mouse Model of Colorectal Cancer

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2014 Jan 11

PMID 24408928

Citations 37

Authors

Jessica E S Shay

Hongxia Z Imtiyaz

Sharanya Sivanand

Amy C Durham

Nicolas Skuli

Sarah Hsu

Vera Mucaj

T S Karin Eisinger-Mathason

Bryan L Krock

Dionysios N Giannoukos

M Celeste Simon

Affiliations

Soon will be listed here.

Abstract

Hypoxia-inducible factors (HIFs) accumulate in both neoplastic and inflammatory cells within the tumor microenvironment and impact the progression of a variety of diseases, including colorectal cancer. Pharmacological HIF inhibition represents a novel therapeutic strategy for cancer treatment. We show here that acriflavine (ACF), a naturally occurring compound known to repress HIF transcriptional activity, halts the progression of an autochthonous model of established colitis-associated colon cancer (CAC) in immunocompetent mice. ACF treatment resulted in decreased tumor number, size and advancement (based on histopathological scoring) of CAC. Moreover, ACF treatment corresponded with decreased macrophage infiltration and vascularity in colorectal tumors. Importantly, ACF treatment inhibited the hypoxic induction of M-CSFR, as well as the expression of the angiogenic factor (vascular endothelial growth factor), a canonical HIF target, with little to no impact on the Nuclear factor-kappa B pathway in bone marrow-derived macrophages. These effects probably explain the observed in vivo phenotypes. Finally, an allograft tumor model further confirmed that ACF treatment inhibits tumor growth through HIF-dependent mechanisms. These results suggest pharmacological HIF inhibition in multiple cell types, including epithelial and innate immune cells, significantly limits tumor growth and progression.

Citing Articles

Hypoxia Increases the Efficiencies of Cellular Reprogramming and Oncogenic Transformation in Human Blood Cell Subpopulations In Vitro and In Vivo.

Moratilla A, Martin D, Cadenas-Martin M, Stokking M, Quesada M, Arnalich F Cells. 2024; 13(11.

PMID: 38891103 PMC: 11172288. DOI: 10.3390/cells13110971.

Is acriflavine an efficient co-drug in chemotherapy?.

Piorecka K, Kurjata J, Gostynski B, Kazmierski S, Stanczyk W, Marcinkowska M RSC Adv. 2023; 13(31):21421-21431.

PMID: 37465576 PMC: 10350790. DOI: 10.1039/d3ra02608f.

Expression of placental glycans and its role in regulating peripheral blood NK cells during preeclampsia: a perspective.

Bueno-Sanchez J, Gomez-Gutierrez A, Maldonado-Estrada J, Quintana-Castillo J Front Endocrinol (Lausanne). 2023; 14:1087845.

PMID: 37206444 PMC: 10190602. DOI: 10.3389/fendo.2023.1087845.

HIF1 inhibitor acriflavine rescues early-onset preeclampsia phenotype in mice lacking placental prolyl hydroxylase domain protein 2.

Sallais J, Park C, Alahari S, Porter T, Liu R, Kurt M JCI Insight. 2022; 7(23).

PMID: 36227697 PMC: 9746916. DOI: 10.1172/jci.insight.158908.

Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.

Piorecka K, Kurjata J, Stanczyk W J Med Chem. 2022; 65(17):11415-11432.

PMID: 36018000 PMC: 9469206. DOI: 10.1021/acs.jmedchem.2c00573.

References

Burke B, Tang N, Corke K, Tazzyman D, Ameri K, Wells M . Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol. 2002; 196(2):204-12. DOI: 10.1002/path.1029. View

Keith B, Johnson R, Simon M . HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011; 12(1):9-22. PMC: 3401912. DOI: 10.1038/nrc3183. View

Wainwright M . Acridine-a neglected antibacterial chromophore. J Antimicrob Chemother. 2001; 47(1):1-13. DOI: 10.1093/jac/47.1.1. View

Bingle L, Brown N, Lewis C . The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196(3):254-65. DOI: 10.1002/path.1027. View

Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T . Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol. 2002; 17(10):1078-83. DOI: 10.1046/j.1440-1746.2002.02853.x. View

Ullman T, Itzkowitz S . Intestinal inflammation and cancer. Gastroenterology. 2011; 140(6):1807-16. DOI: 10.1053/j.gastro.2011.01.057. View

Pan Y, Oprysko P, Asham A, Koch C, Simon M . p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene. 2004; 23(29):4975-83. DOI: 10.1038/sj.onc.1207657. View

Murdoch C, Giannoudis A, Lewis C . Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004; 104(8):2224-34. DOI: 10.1182/blood-2004-03-1109. View

Murdoch C, Muthana M, Coffelt S, Lewis C . The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008; 8(8):618-31. DOI: 10.1038/nrc2444. View

10.

Murdoch C, Lewis C . Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer. 2005; 117(5):701-8. DOI: 10.1002/ijc.21422. View

11.

Bertout J, Patel S, Simon M . The impact of O2 availability on human cancer. Nat Rev Cancer. 2008; 8(12):967-75. PMC: 3140692. DOI: 10.1038/nrc2540. View

12.

Hans W, Scholmerich J, Gross V, Falk W . The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur J Gastroenterol Hepatol. 2000; 12(3):267-73. DOI: 10.1097/00042737-200012030-00002. View

13.

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

14.

Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S . Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut. 1996; 39(1):87-92. PMC: 1383238. DOI: 10.1136/gut.39.1.87. View

15.

Lewis J, Lee J, Underwood J, Harris A, Lewis C . Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol. 1999; 66(6):889-900. DOI: 10.1002/jlb.66.6.889. View

16.

Tanner A, Arthur M, Wright R . Macrophage activation, chronic inflammation and gastrointestinal disease. Gut. 1984; 25(7):760-83. PMC: 1432607. DOI: 10.1136/gut.25.7.760. View

17.

Keith B, Simon M . Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007; 129(3):465-72. PMC: 3150586. DOI: 10.1016/j.cell.2007.04.019. View

18.

Lim M, Ahn J, Han Y, Yu C, Kim M, Lee S . Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis. Int J Biochem Cell Biol. 2012; 44(8):1214-22. DOI: 10.1016/j.biocel.2012.04.022. View

19.

Vakkila J, Lotze M . Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004; 4(8):641-8. DOI: 10.1038/nri1415. View

20.

Imtiyaz H, Williams E, Hickey M, Patel S, Durham A, Yuan L . Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest. 2010; 120(8):2699-714. PMC: 2912179. DOI: 10.1172/JCI39506. View